Symmetric vaccine efficacy
Open Access
- 1 July 2026
- journal article
- Published by Oxford University Press (OUP) in Biometrics
- Vol. 82 (3)
Abstract
Traditional measures of vaccine efficacy (VE) are inherently asymmetric, constrained above by 1 but unbounded below. As a result, VE estimates and corresponding confidence intervals (CIs) can extend far below zero, making interpretation difficult and potentially obscuring whether the apparent effect reflects true harm or simply statistical uncertainty. The proposed symmetric vaccine efficacy (SVE) is a bounded and interpretable alternative to VE that maintains desirable statistical properties while resolving these asymmetries. SVE is defined as a symmetric transformation of infection risks, with possible values within $[-1, 1]$, providing a common scale for both beneficial and harmful vaccine effects. This paper describes the relationship between SVE and traditional VE, considers inference about SVE, and illustrates the utility of the proposed measure by reanalyzing data from a randomized trial of a candidate HIV vaccine. Open-source tools for computing estimates of SVE and corresponding CIs are available in R through the sve package.
Keywords
All Related Versions
Funding Information
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health (R37 AI054165)
This publication has 12 references indexed in Scilit:
- Observed negative vaccine effectiveness could be the canary in the coal mine for biases in observational COVID-19 studiesInternational Journal of Infectious Diseases, 2023
- Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacyDialogues in Health, 2022
- Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe OutcomesJAMA Network Open, 2022
- Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort studymedRxiv, 2021
- Estimation of Treatment Effects in Randomized Trials With Non-Compliance and a Dichotomous OutcomeJournal of the Royal Statistical Society Series B: Statistical Methodology, 2007
- Symmetrized Percent Change for Treatment ComparisonsThe American Statistician, 2006
- Placebo‐Controlled Phase 3 Trial of a Recombinant Glycoprotein 120 Vaccine to Prevent HIV‐1 InfectionThe Journal of Infectious Diseases, 2005
- Understanding the relationship between relative and absolute riskCancer, 1996
- Direct and Indirect Effects in Vaccine Efficacy and EffectivenessAmerican Journal of Epidemiology, 1991
- New Light on the Correlation Coefficient and its TransformsJournal of the Royal Statistical Society Series B: Statistical Methodology, 1953